Clinical Trial Update: A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of laropiprant (MK-0524) in participants with moderate to severe erythematotelangiectatic rosacea. The study is reported as comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rosacea

Drugs mentioned

• Laropiprant (laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rosacea | Phase 1 | Status: COMPLETED